ESCO TECHNOLOGIES INC 8-K

What Happened
ESCO Technologies Inc. announced on April 15, 2026 that it entered into a purchase agreement to buy Megger Group Limited from TBG AG for approximately $2.35 billion. The consideration is roughly $922 million in cash and 5.10 million shares of ESCO common stock (subject to a post‑closing net debt/working capital adjustment payable in cash). The transaction is subject to customary closing conditions, including U.S. Hart‑Scott‑Rodino clearance, CFIUS review under the Defense Production Act, DCSA and other foreign regulatory approvals. The agreement includes customary warranties, termination rights and seller protections; the outside closing date is April 15, 2027 (with certain automatic extensions).

Key Details

• Purchase Agreement dated April 15, 2026 between ESCO and seller TBG AG to acquire Megger Group Limited (England & Wales) for ~ $2.35B: $922M cash + 5.10M ESCO shares.
• Shareholder Agreement (to be effective at closing) gives Seller a designated board seat while Seller Holders own ≥50% of the Consideration Shares, transfer restrictions for 12 months, standstill limits (generally ≤24.5% ownership without Board consent), and customary registration, preemptive and information rights.
• Financing: ESCO entered a Commitment Letter with JPMorgan (April 15, 2026) pursuing up to $1.5B of “Best Efforts” secured facilities (including a $500M revolver and term loans); alternative Backstop and Bridge facilities are described to cover shortfalls. Proceeds will fund the cash portion, refinance indebtedness, and pay transaction costs.
• Closing is conditional on multiple regulatory clearances (HSR, CFIUS, DCSA, foreign merger/foreign investment approvals); parties have specified termination and limited pre‑closing breach remedies.

Why It Matters
This is a sizable acquisition for ESCO (~$2.35B) funded with a mix of cash, newly issued stock and committed debt facilities, which may meaningfully affect ESCO’s capital structure and share count if completed. The Seller will have short‑term governance and transfer restrictions via the Shareholder Agreement (including a potential board seat), and the deal is subject to material regulatory approvals (CFIUS/HSR/DCSA) that could delay or block closing. The filing also highlights standard integration and execution risks and notes that certain seller warranties are limited and qualified by confidential schedules, which investors should consider when assessing potential impact.